(Q37902697)

25 August 2017

0 references

Immunohistochemical biomarkers for bladder cancer prognosis (English)

1 reference

25 August 2017

0 references

1 reference

1 reference

2

1 reference

25 August 2017

8

Pierre I Karakiewicz

1 reference

25 August 2017

7

Maxine Sun

1 reference

25 August 2017

10

Shahrokh F Shariat

1 reference

25 August 2017

5

Thomas F Chromecki

1 reference

25 August 2017

1

Kazuhito Matsushita

1 reference

25 August 2017

4

Shiro Baba

1 reference

25 August 2017

6

Harun Fajkovic

1 reference

25 August 2017

Kazumasa Matsumoto

3

1 reference

25 August 2017

Douglas S Scherr

series ordinal

9

1 reference

25 August 2017

publication date

20 July 2011

1 reference

International Journal of Urology

25 August 2017

published in

1 reference

25 August 2017

volume

18

1 reference

25 August 2017

issue

9

1 reference

25 August 2017

page(s)

616-629

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

The updated EAU guidelines on muscle-invasive and metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Bladder cancer: epidemiology, staging and grading, and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Molecular markers for detection, surveillance and prognostication of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Epigenetic markers as promising prognosticators for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Statistical consideration for clinical biomarker research in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Prognostic value of p53 for high risk superficial bladder cancer with long-term followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Nuclear cyclin D1: an oncogenic driver in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Apoptosis and chemotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Apoptosis by death factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Survivin: role in diagnosis, prognosis, and treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

A survivin gene signature predicts aggressive tumor behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Survivin, versatile modulation of cell division and apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Survivin expression is associated with bladder cancer presence, stage, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Survivin: a promising biomarker for detection and prognosis of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Angiogenesis in bladder cancer--prognostic marker and target for future therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Targeting angiogenesis in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Targeting EGFR in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Somatic mutation of PTEN in bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2011.02809.X

10.1111/J.1442-2042.2011.02809.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference